Navigation Links
Phase III studies show linagliptin improved blood glucose control in Asian adults with type 2 diabetes
Date:6/22/2013

ents and 0.0 percent of placebo patients. In addition, investigator-defined hypoglycemia occurred in 0.5 percent of linagliptin patients and 0.0 percent of placebo patients in the monotherapy study, and in 1.0 percent of patients in both groups of the add-on study.3, 4

About the Studies
The first study was a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of linagliptin monotherapy for 24 weeks in Asian patients with inadequately controlled type 2 diabetes mellitus. The study included a total of 300 patients with T2D from China (n=261), Malaysia (n=22) and the Philippines (n=17). Patients who were treatment naïve or who had been treated with one antihyperglycemic drug were randomized to either linagliptin 5 mg daily or placebo following a 4-week washout period of prior drugs. The primary endpoint was change from baseline in mean HbA1c after 24 weeks.3 Mean HbA1c levels at baseline were 7.95 percent for patients in the linagliptin group and 8.09 percent for patients in the placebo group.

The second study, also a randomized, double-blind, placebo-controlled trial, evaluated the efficacy and safety of linagliptin as add-on therapy to metformin in Asian patients with inadequately controlled type 2 diabetes mellitus. The study included a total of 306 patients with T2D from China (n=265), Malaysia (n=17) and the Philippines (n=24). Antihyperglycemic drugs other than metformin were washed out for 4 weeks prior to randomization to either linagliptin 5mg daily or placebo added to metformin. The primary endpoint of the study was change from baseline in mean HbA1c after 24 weeks.4 Mean HbA1c levels at baseline were 7.99 percent for patients in the linagliptin group and 8.00 percent for pa
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014  CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced an ... lead drug candidate, aldoxorubicin.  The presentation, titled, "Drug ... will be given by Sant P. Chawla ... Center and principal investigator of the Company,s ongoing ...
(Date:10/30/2014)... -- , La fórmula de leche ... tolerancia a la proteína de leche de vaca  ... leche de la vaca (APLV) es la principal alergia alimentaria ... APLV se trataba eliminando las proteínas lácteas de ... posible adquirir tolerancia oral en un número significativo ...
(Date:10/30/2014)... Oct. 30, 2014  TWi Pharmaceuticals, Inc. today announced ... States Food and Drug Administration (FDA) on its Abbreviated ... 23 mg, the generic equivalent to Eisai Inc.,s Aricept® ... patients. TWi Pharmaceuticals is preparing to launch ... subsidiary, TWi Pharmaceuticals USA , at ...
Breaking Medicine Technology:CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3
... 28, 2011 Nile Therapeutics, Inc. (Nasdaq: ... novel therapeutics for heart failure patients, today announced plans ... ) on the clinical development of Nile,s proprietary natriuretic ... disease applications. "We are very pleased to ...
... Feb. 28, 2011 PAREXEL International Corporation (Nasdaq: ... presenting at the Raymond James Investors Conference in Orlando, FL. ... be making a presentation on PAREXEL at 2:50 p.m.  ET ... of this presentation will be available through the "Investors" ...
Cached Medicine Technology:Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 2Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 3PAREXEL International to Present at Raymond James Investors Conference 2
(Date:10/28/2014)... that aims to make personalized medicine a reality for ... across British Columbia. , The "Genomics for Precision Drug ... of its kind in North America. The project is ... (BCPhA), with the research component led by a team ... Sciences (UBC). It will position the pharmacist as the ...
(Date:10/27/2014)... price tag for informal caregiving of elderly people by ... $522 billion a year, according to a new RAND ... care at minimum wage would cost $221 billion, while ... $642 billion annually. , The study, published online ... estimates about the value of informal caregiving by making ...
(Date:10/27/2014)... different role than previously thought in the opening and ... out of our cells, researchers at Johns Hopkins report. ... right concentrations of sodium and calcium ions in cells ... processes. The new study reveals that a form of ... channels wide. The finding is likely to bring new ...
(Date:10/27/2014)... The 2014 Sharp­Brains Vir­tual ... world’s top sci­en­tists and inno­va­tors work­ing on ... via neuroscience-based inno­va­tion. , Indi­vid­u­als and insti­tu­tions ... bil­lion in 2014 in web-based, mobile and ... func­tion. Growth is poised to con­tinue, fueled ...
(Date:10/27/2014)... Agency (EMA), an EU agency, has gathered information on ... European ADR database, EudraVigilance. Both authorities and pharmaceutical companies ... the database, which provides new knowledge about unknown and ... drug reaction reports on asthma medications approved for – ... (2007 to 2011). In the light of the total ...
Breaking Medicine News(10 mins):Health News:Genomics helps pharmacists target the right drugs for the right patient 2Health News:Cost of informal caregiving for US elderly is $522 billion annually, study finds 2Health News:200 Experts to Discuss and Shape the Future of Brain Health, Gathered Around a Virtual Table 2Health News:200 Experts to Discuss and Shape the Future of Brain Health, Gathered Around a Virtual Table 3Health News:200 Experts to Discuss and Shape the Future of Brain Health, Gathered Around a Virtual Table 4Health News:Adverse drug reactions in children following use of asthma medications 2
... a pregnancy take a general multivitamin supplement in the ... them and their baby, however a recent survey suggests ... in unborn babies but many women do not consider ... based on a recent survey. The survey conducted by ...
... has donated $50,000 to Gilda's Club Worldwide, //an organization that ... in a statement: "When children have cancer, or when their ... places they can turn to for support." , ,"Gilda's ... helping children in need, and so I am very happy ...
... People suffering from Alzheimer’s disease can have loss of ... to test their visual clarity., ,Alzheimer’s disease affects ... symptoms of the disease are decreasing memory, ability to ... Alzheimer’s disease are often disoriented too much to be ...
... may lack a gene called estrogen receptor beta and not ... research funded by National Institute of Environmental Health Sciences reported ... role in moving the egg outside the ovary to be ... is found otherwise throughout in the female reproductive tissues, women ...
... people were infected with HIV by 2004.// This puts the prevalence ... South Africa 's total population is 46.9 million. , ... far higher than the estimate of 4.5 million given by the ... ,The health department said that between 6.29 million ...
... microRNAs may be responsible for birth defects, cancer and ... Institute have used genetically modified mice to see how ... animals. When the mice were grown without the microRNA ... limbs., ,MicroRNA (miRNA) are small RNA molecules that ...
Cached Medicine News:Health News:Britney Spears Donates $50 000 To Support Cancer Patients 2Health News:Britney Spears Donates $50 000 To Support Cancer Patients 3Health News:Over Six Million HIV Infected People In South Africa- Finds A Survey 2Health News:Over Six Million HIV Infected People In South Africa- Finds A Survey 3
Solid lower plate with outside width 15 mm. Open serrated upper plate with inside dimensions 9 x 12 mm. Serrated handle with locking thumb screw and polished finish....
Oval solid 15 mm wide lower plate. Open upper plate with inside dimensions 11 mm x 8 mm. Serrated handle with locking thumb screw and polished finish....
1 mm smooth 45 degrees angled jaws. Cross action serrated handle with polished finish....
Solid lower plate with outside width 28 mm. Open upper plate. Serrated handle with locking thumb screw and polished finish. Right....
Medicine Products: